COMMUNIQUÉS West-GlobeNewswire

FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation

15/02/2018 - 17:58

– PDUFA date set for August 21, 2018 – CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism to treat cancer and rare genetic [...]

Diaxonhit : Distribution exclusive de la plateforme de biologie moléculaire VERIGENE®

15/02/2018 - 17:54

Distribution exclusive de la plateforme de biologie moléculaire VERIGENE® Diaxonhit devient, par l'intermédiaire de sa filiale eurobio-ingen, le distributeur exclusif de la gamme de biologie moléculaire VERIGENE® de la [...]

GUERBET : 2017 revenue at constant exchange rates: €812.4 million; +4.7%

15/02/2018 - 17:47

Villepinte, February 15, 2018 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €807.1 million at December 31, 2017, up by 4.0% at current [...]

GUERBET : Chiffre d'affaires 2017 à taux de change constant : 812,4 M€ ; +4,7%

15/02/2018 - 17:47

Villepinte, le 15 février 2018 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, publie un chiffre d'affaires de 807,1 M€ au 31 décembre 2017, en [...]

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

15/02/2018 - 17:43

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology [...]

PetVivo Holdings, Inc. Adds Special Revenue Consultant Approaching Commercial Production

15/02/2018 - 17:22

MINNEAPOLIS, Feb. 15, 2018 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. ( www.petvivo.com ) (OTCMARKET:PETV) an emerging biomedical device Company, is moving Mr. David Merrill, a member of the Board of Directors, to cover [...]

JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast Cancer

15/02/2018 - 17:15

SALT LAKE CITY, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage [...]

Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder

15/02/2018 - 17:06

SAN DIEGO, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a clinical-stage, women’s biopharmaceutical company, today announced that it has met the funding requirement for obtaining an exclusive [...]

Sales of Olainfarm in January Exceed 9 Million Euros

15/02/2018 - 17:03

Olaine, 2018-02-15 17:03 CET (GLOBE NEWSWIRE) -- January 2018, consolidated sales Sales, Thsnd. EUR Changes to January 2017 Share in total sales Latvia 2 922 18% 32% Russia 1 716 -27% 19% Belarus 1 696 5% 18% Ukraine 1 [...]

Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer

15/02/2018 - 17:00

– Confirmed partial responses observed in five of six evaluable patients with HRAS mutant HNSCC – – Rate of enrollment increasing with three additional patients enrolled in four months – – Initiation of registrational [...]

Amedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call Date

15/02/2018 - 16:30

BATON ROUGE, La., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED ), announced today that it will report results for the fourth quarter and year ended December 31, 2017 after the market closes on February [...]

Sienna Announces February Dividend

15/02/2018 - 16:00

MARKHAM, Ontario, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA ) today announced a dividend of $0.075 per common share of the Company (each, a “Common Share”) for [...]

Solon Eiendom ASA : Notice of extraordinary general meeting

15/02/2018 - 15:13

(Oslo, 15 February 2018) Solon Eiendom ASA (OSE: SOLON), calls for the extraordinary general meeting to be held at the company's offices in Olav Vs gate 5, 0161, Oslo, Norway on 09 March 2018 at 10 am (CET). The notice [...]

Immunovaccine Announces Closing of $14.375 million Bought Deal Offering with Over-allotment option exercised in full

15/02/2018 - 15:00

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, N.S., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (“Immunovaccine” or the “Corporation”) (TSX: IMV ) (OTCQX:IMMVF), a [...]

Immunovaccine annonce la clôture d’un placement par voie de prise ferme de 14,375 millions de dollars compte tenu de l’option de surallocation intégralement exercée

15/02/2018 - 15:00

NE PAS DISTRIBUER À DES AGENCES DE TRANSMISSION DES ÉTATS-UNIS NI DIFFUSER AUX ÉTATS-UNIS HALIFAX, N.S., 15 févr. 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (« Immunovaccine » ou la « société ») (TSX: IMV ) (OTCQX: [...]

Precipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance

15/02/2018 - 14:38

NEW HAVEN, Conn., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO ) announced today its launch of the first lung cancer treatment resistance panel specifically for the critical mutations T790M and C797S [...]

Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy

15/02/2018 - 14:30

DURHAM, N.C., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ: ARGS ), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis [...]

Scythian Biosciences Announces Appointment of Professor Michael Barnes as Chief Medical Officer

15/02/2018 - 14:20

- Influential voice in medical cannabis policy in Europe - A leading world authority in neurological rehabilitation TORONTO, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the “ Company ” or “ Scythian [...]

CORRECTION - Shire Announces FDA Acceptance of sBLA for CINRYZE® for Pediatric Hereditary Angioedema Use

15/02/2018 - 14:12

**CORRECTION - Shire Announces FDA Acceptance of sBLA for CINRYZE ® (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use FDA assigns an action date of June 20, 2018 If approved, CINRYZE will be the [...]